IBA (Ion Beam Applications) has entered into an agreement with Bayer Schering Pharma, Germany for chemical process development and clinical trial doses supply of Florbetaben, a PET tracer in development for the detection of beta-amyloid deposits in the brain, a hallmark of Alzheimer’s disease.  

Under the terms of the agreement, IBA will manufacture and supply Bayer and its trial partners with doses of the compound Florbetaben for clinical trials.

The Louvain-la-Neuve, Belgium-based IBA said it will develop a large-scale manufacturing process on Synthera, a multi-purpose automated synthesizer, and upgrade its PET manufacturing network in order to ensure availability of the compound for the clinical trials.